Based on available data from study 6201, it is currently uncertain what is the best strategy to ensure that diarrhoea is adequately managed, and what is the optimal strategy for anti-diarrhoeal prophylaxis.The applicant has committed to further study appropriate strategies for anti-diarrhoeal management (see RMP). Once identified, this would contribute to the favourable use of neratinib in clinical practice. In the meantime, relevant measures are agreed to help mitigate this risk (see RMP and PI).